Rep. Weiss' (D-N.Y.) L-tryptophan hearing
Executive Summary
FDA's "failure to aggressively regulate the dietary supplement L-tryptophan" will be the subject of a July 18 House Government Operations/Human Resources and Intergovernmental Relations Subcommittee meeting. The hearing will focus on whether more aggressive FDA action could have prevented the 1989 outbreak of Eosinophilia Myalgia Syndrome linked to L-tryptophan.